Arcadia Biosciences, Inc. carries no debt; cash flow comfortably covers obligations.

Arcadia Biosciences, Inc.'s free cash flow has increased -50.86% from $-9.64M last year to $-4.74M, signaling increasing performance

Arcadia Biosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Arcadia Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Arcadia Biosciences, Inc. has a net cash position, so leverage is healthy.

Arcadia Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Arcadia Biosciences, Inc.'s profit margin has decreased (40.46%) in the last year from -139.50% to -195.94%, signaling decreasing performance

Arcadia Biosciences, Inc.'s short-term assets of $6.36M exceed its short-term liabilities of $2.06M

Arcadia Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arcadia Biosciences, Inc.'s return on equity of -219.35%, is lower than 15.00%, indicating bad performance

Arcadia Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arcadia Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Arcadia Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Arcadia Biosciences, Inc. has negative free cash flow, indicating cash burn

Arcadia Biosciences, Inc.'s yearly earnings has increased -66.77% since last year from $-7.04M to $-2.34M, signaling increasing performance

Arcadia Biosciences, Inc.'s yearly revenue has decreased 3.71% since last year from $5.04M to $4.86M, signaling decreasing performance

ROIC -241.36% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Arcadia Biosciences, Inc.'s 3-year revenue CAGR of -13.16% is negative, indicating declining revenue over the past 3 years

Arcadia Biosciences, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Arcadia Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Arcadia Biosciences, Inc. has insufficient data to evaluate this check.

Arcadia Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcadia Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Arcadia Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Arcadia Biosciences, Inc. is overvalued relative to its fair value price of -45.03 based on Earnings Fair Value model

Arcadia Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcadia Biosciences, Inc. has a price-to-book ratio of 0.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Arcadia Biosciences, Inc. has a price-to-sales ratio of 0.19x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue